Oct 22 2012 8:00AM - Oct 24 2012 4:00PM
Capital Hilton 1001 16th Street NW, Washington, DC 20036-5794 USA
Capital Hilton 1001 16th Street NW, Washington, DC 20036-5794 USA
Co-sponsored with NORD (National Organization for Rare Disorders)
The Meeting For All Stakeholders in the Rare Disease/Orphan Product Community
This annual meeting where stakeholders - patients, patient organizations, researchers, drug and device companies, investors, thought leaders and government – meet to focus on rare diseases and orphan product research, development and access. At this year’s meeting, we seek to gain a common understanding of the current and emerging challenges, opportunities, and strategies for working together effectively to shape a better future for rare diseases and orphan drugs. It is important to remember none of us can get there alone. The 2011 meeting brought together more than 300 stakeholders, and this year’s event promises even more.
The format of the meeting includes both plenary and smaller group sessions. High-level plenary sessions will open a collaborative dialogue among leading researchers, company officials, investors, patient organizations and government leaders. Smaller group sessions are organized around three central themes: policy, research and regulation and special challenges. These sessions are intended to promote advancements in science, care and other considerations that will address the needs of the 30 million Americans with rare diseases. Topics include the current and emerging drug development environment, reenactment of the Prescription Drug and Medical Device User Fee Act, an update on NIH’s new National Center Advancing Translational Science, and many others.
Patient Organizations/Patients are invited to attend the US Conference on Rare Diseases and Orphan Products at a reduced registration fee of $400.
Please submit a registration form by fax to 215.442.6199
Questions: Contact Carrie Dunn at the DIA office by telephone 215.442.6181 or email Carrie.Dunn@diahome.org
Who Should Attend
- Researchers from academia and drug and device companies
- Patient organizations and those interested in creating one
- Senior managers from drug and device companies interested in rare diseases
- Investors focused on the future of orphan product development
- Policy experts who are concerned about federal or state policies that affect patients with rare diseases
- Providers of services to the rare disease community, including insurance providers and health care professionals
- Government officials responsible for rare disease research and orphan product oversight
No comments:
Post a Comment